LEGN Legend Biotech Corp
Price Chart
Executive Summary
Legend Biotech presented first-in-human Phase 1 data for LB2102 (DLL3-targeted CAR-T) in solid tumors at ASCO 2026, showing an ORR of 28.6% at the highest dose level and a manageable safety profile. New CARVYKTI data reinforced durable efficacy with 30-month OS >85% in CARTITUDE-4 responders. The filing validates Legend's pipeline expansion beyond multiple myeloma and supports the commercial franchise.
Actionable Insight
Expect a positive short-term reaction as ASCO data de-risk LB2102 and reinforce CARVYKTI's durability. Near-term upside potential from pipeline re-rating. Monitor for further phased data and potential milestone payments from Novartis.
Key Facts
- LB2102 Phase 1 overall ORR: 20% (4/20); at dose level 3: ORR 28.6%, DCR 78.6%.
- LB2102 showed no dose-limiting toxicities or treatment-related deaths; all CRS were Grade 2.
- CARVYKTI CARTITUDE-4 subgroup analysis: 30-month OS >85% in responders; no IEC-associated Parkinsonism.
- CARVYKTI is commercially available in 18 countries and has treated >10,000 patients.
- LB2102 is licensed to Novartis under a 2023 agreement; Legend conducts the US Phase 1 trial.
Financial Impact
Not directly quantified; positive readout could accelerate LB2102 development milestones and support CARVYKTI uptake.
Risk Factors
- LB2102 is early phase (n=20); larger trials may not confirm efficacy.
- CAR-T in solid tumors faces biological hurdles; safety signals (ICANS, CRS) remain elevated.
- Competition from other BCMA and DLL3-targeted therapies could limit commercial opportunity.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003825 |
| Document: f6k_060126.htm | 0001171843-26-003825 |
| Document: 0001171843-26-003825-index-headers.html | 0001171843-26-003825 |
| Document: 0001171843-26-003825-index.html | 0001171843-26-003825 |
| Document: 0001171843-26-003825.txt | 0001171843-26-003825 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
6-K
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $32.84 (−9.48%) |
|
Jun 2, 2026
3d ago
|
Press Release
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $32.84 (−9.48%) |
|
Jun 1, 2026
4d ago
|
6-K
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $32.84 (+28.73%) |
|
Jun 1, 2026
4d ago
|
Press Release
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $32.84 (+28.73%) |
|
May 21, 2026
14d ago
|
6-K
| — | awaiting T+1 | — | — |
|
May 21, 2026
14d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 12, 2026
24d ago
|
6-K
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $32.84 (+16.21%) |
|
May 12, 2026
24d ago
|
Press Release
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $32.84 (+16.21%) |
|
Apr 28, 2026
5w ago
|
Press Release
| $23.56 $22.77 | ▼ −3.35% | ▼ −3.34% | $32.84 (+39.39%) |
|
Apr 14, 2026
7w ago
|
6-K
| $18.69 $20.52 | ▲ +9.79% | ▲ +9.02% | $32.84 (+75.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access